Modeling cost-effectiveness of pharmaceuticals in Alzheimer's disease.

abstract：:Prostate cancer is the most common non-skin cancer in American men, and prostate-specific antigen (PSA) testing is its common screening procedure. In May 2012, the US Preventive Services Task Force recommended against PSA-based screening. These recommendations contradict the current recommendations of other organizati...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Garg V,Gu NY,Borrego ME,Raisch DW

更新日期：2013-06-01 00:00:00

abstract：:Rates of antibiotic resistance in Pseudomonas aeruginosa are increasing worldwide. The multidrug-resistant (MDR) phenotype in P. aeruginosa could be mediated by several mechanisms including multidrug efflux systems, enzyme production, outer membrane protein (porin) loss and target mutations. Currently, no internationa...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hirsch EB,Tam VH

更新日期：2010-08-01 00:00:00

abstract：:The Dutch basic health insurance is based on the principles of regulated competition. This implies that insurers and providers compete on price and quality while the regulator sets certain rules to achieve public objectives such as solidarity. Two regulatory aspects of this scheme are that insurers are not allowed to ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： van Kleef RC,van de Ven WP,van Vliet RC

更新日期：2013-12-01 00:00:00

abstract：:The main analytic problems for assessing the equality of means of healthcare costs are the skewed and heteroscedastic nature of the distribution of healthcare costs and the occurrence of persons with zero cost values. Without taking these special features into consideration, any statistical method may lead to the wron...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Zhou XH,Ramsey S

更新日期：2003-10-01 00:00:00

abstract：:Economists' approaches to priority setting focus on the principles of opportunity cost, marginal analysis and choice under scarcity. These approaches are based on the premise that it is possible to design a rational priority setting system that will produce legitimate changes in resource allocation. However, beyond is...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Peacock SJ,Mitton C,Ruta D,Donaldson C,Bate A,Hedden L

更新日期：2010-10-01 00:00:00

abstract：AIM:To evaluate patient perception of the onset of action and overall satisfaction with a fast-dissolving tablet (FDT) formulation of ebastine in patients with intermittent or persistent allergic rhinitis. PATIENTS AND METHODS:This was a cross-sectional, multicenter, pharmacy-based survey involving adult patients (>18...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Roger A,Fortea J,Mora S,Artés M

更新日期：2008-08-01 00:00:00

abstract：:This review addresses hidden costs associated with the Bayer VERSANT assay, Roche AMPLICOR MONITOR test and COBAS AMPLICOR MONITOR test and how these influence the final per reportable cost to a testing laboratory in resource-rich and -poor countries. An in-depth evaluation and recommendation of the most cost-effectiv...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Elbeik T,Chen YM,Soutchkov SV,Loftus RA,Beringer S

更新日期：2003-08-01 00:00:00

abstract：BACKGROUND:Four hurdles associated with economic evaluations in welfare interventions were identified and discussed in a previous published literature review. These hurdles include (i) 'Ignoring the impact of condition-specific outcomes', (ii) 'Ignoring the impact of QoL externalities', (iii) 'Calculation of costs from...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Schepers J,Plaete J,De Bourdeaudhuij I,Annemans L,Simoens S

更新日期：2017-08-01 00:00:00

abstract：:Electronic medical records (EMRs) have become a common source of data for outcomes research. This review discusses trends in EMR data use for outcomes research as well as strengths and limitations, and likely future developments to help optimize value and use of EMR data for outcomes research. EMR-based studies report...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Lin J,Jiao T,Biskupiak JE,McAdam-Marx C

更新日期：2013-04-01 00:00:00

abstract：:The prevalence of multiple chronic conditions (MCC) is increasing among individuals of all ages. MCC are associated with poor health outcomes. The presence of MCC has profound healthcare utilization and cost implications for public and private insurance payers, individuals, and families. Investigators have used a vari...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Sambamoorthi U,Tan X,Deb A

更新日期：2015-01-01 00:00:00

abstract：:The pharmaceutical sector has been established as the primary cost driver in health. The scope of this paper is to explore the drivers of pharmaceutical expenditure in Cyprus by decomposing sales and assessing impact of prices, volumes and substitution effect. We used a statistical approach to decompose the growth of ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Petrou P

更新日期：2014-04-01 00:00:00

abstract：OBJECTIVE:To assess the cost-effectiveness of single pill fixed dose triple combination therapy vs. free triple combination therapy for the prevention of cardiovascular events among patients with hypertension. METHODS:A Markov model with a five year cycle was constructed. Two decision models incorporating strict and m...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wang X,Chen H,Ej E,Wu J,Serna O,Paranjpe R,Abughosh S

更新日期：2020-08-01 00:00:00

abstract：:Growing understanding of the mechanisms and epidemiology of neonatal herpes simplex virus acquisition allows for the development of a new management of the pregnant patient, one that will reduce the risk of transmitting herpes to the newborn. Maternal herpes simplex virus infection, especially acquired during pregnanc...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Baker DA

更新日期：2005-12-01 00:00:00

abstract：:Despite the intense debates over state or private sector dominance in healthcare finance and provision, there are no clear winners. Failed models exist on either end of the ideological spectrum and no country in the world has one that is purely public or purely private. Neither does a perfect public-private mix exist;...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Lim MK

更新日期：2006-12-01 00:00:00

abstract：:The purpose of this article is to provide a critical evaluation of the available literature describing the economic burden of multiple sclerosis and to assess the gaps in information. The studies included in this review describe costs in patients categorized into severity groups according to the Expanded Disability St...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Orlewska E

更新日期：2006-04-01 00:00:00

abstract：:Chronic obstructive pulmonary disease is a major cause of morbidity and mortality throughout the world. Standard management includes avoidance of causative factors such as smoking, and pharmacological therapy with combinations of inhaled and/or oral bronchodilators and corticosteroids. Lung transplantation is an estab...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Reed A,Williams T,Snell G

更新日期：2003-12-01 00:00:00

abstract：:This paper acknowledges the difficulties of providing access to innovative drugs in some jurisdictions under the patent system and it contributes to the current debate on mechanisms aimed at facilitating such access. We employ a highly stylized static model of two markets (North and South) to analyse the conditions un...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Antoñanzas F,Rodríguez-Ibeas R,Juárez-Castelló CA

更新日期：2014-10-01 00:00:00

abstract：AIM:Limitations of vitamin K antagonists (VKAs) include frequent monitoring, dietary restrictions and drug interactions. This study conducted an indepth exploration of perspectives of VKA therapy in respondents with atrial fibrillation or venous thromboembolism. METHODS:A total of 60 respondents, recruited from the UK...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wild D,Murray M,Donatti C

更新日期：2009-10-01 00:00:00

abstract：:Parkinson's disease (PD) is the second most common neurodegenerative disease. There are no clinical trials comparing all available pharmacological therapies for the treatment of early PD. The objective of this review is to indirectly analyze the efficacy of antiparkinson drugs currently available in Latin America. A s...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Márquez-Cruz M,Díaz-Martínez JP,Soto-Molina H,De Saráchaga AJ,Cervantes-Arriaga A,Llorens-Arenas R,Rodríguez-Violante M

更新日期：2016-01-01 00:00:00

abstract：INTRODUCTION:Pharmacogenomic testing has the potential to greatly benefit patients by enabling personalization of medication management, ensuring better efficacy and decreasing the risk of side effects. However, to fully realize the potential of pharmacogenomic testing, there are several important issues that must be a...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Moyer AM,Caraballo PJ

更新日期：2017-12-01 00:00:00

abstract：:The assessment of longitudinal change in subjective patient-reported outcomes such as health-related quality of life (HRQoL) is a key component of many clinical and research evaluations. A major goal of measuring patient-reported HRQoL is to determine to what extent changes in HRQoL reports over time represent true ch...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hamidou Z,Dabakuyo TS,Bonnetain F

更新日期：2011-10-01 00:00:00

abstract：OBJECTIVES:This cross-sectional study examined the prevalence and burden of major depressive disorder (MDD) among adults in urban China. METHODS:Data were included from the 2012 China National Health and Wellness Survey. Respondents self-reporting physician diagnosis of depression and screening positive for MDD (Patie...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Gupta S,Goren A,Dong P,Liu D

更新日期：2016-06-01 00:00:00

abstract：:By 2018, Medicare payments will be tied to quality of care. The Centers for Medicare and Medicaid Services currently use quality-based metric for some reimbursements through their different programs. Existing and future quality metrics will rely on risk adjustment to avoid unfairly punishing those who see the sickest,...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Al Kazzi ES,Hutfless S

更新日期：2015-01-01 00:00:00

abstract：:Adalimumab is a monoclonal antibody that inhibits TNF, an osteogenic cytokine involved in the pathogenesis of chronic, disabling inflammatory diseases. Adalimumab is indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. It alleviates the symptoms of these diseases, preven...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Gladman DD,Brown RE

更新日期：2008-04-01 00:00:00

abstract：:This article reviews the literature reporting empirically determined symptom clusters in patients with metastatic cancer. A literature search was conducted on symptom clusters within heterogeneous metastatic cancer patient populations using MEDLINE, EMBASE, and CINAHL. Studies examining predetermined symptom clusters ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Thavarajah N,Chen E,Zeng L,Bedard G,Di Giovanni J,Lemke M,Lauzon N,Zhou M,Chu D,Chow E

更新日期：2012-10-01 00:00:00

abstract：:Lung cancer is a leading cause of cancer deaths for both men and women across the world. In the past, studies on lung cancer have focused on traditional end points such as survival, disease-free survival or local control. More recently, investigators have begun to appreciate the importance of health-related quality-of...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Siddiqui F,Konski AA,Movsas B

更新日期：2010-12-01 00:00:00

abstract：BACKGROUND:Although Health Technology Assessment (HTA) is increasingly used to support evidence-based decision-making in health care, several barriers and facilitators for the use of HTA have been identified. This best-worst scaling (BWS) study aims to assess the relative importance of selected barriers and facilitator...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Feig C,Cheung KL,Hiligsmann M,Evers SMAA,Simon J,Mayer S

更新日期：2018-04-01 00:00:00

abstract：:Osteoporosis is a public health threat to approximately 44 million individuals in the USA, or 55% of men and women over the age of 50 years. The primary goal of osteoporosis management is to prevent fracture, the most devastating consequence. Risk factors and bone mineral density can be assessed to determine appropria...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hansen LB

更新日期：2006-10-01 00:00:00

abstract：:In recent years, the quest for more comprehensiveness, structure and transparency in reimbursement decision-making in healthcare has prompted the research into alternative decision-making frameworks. In this environment, multi-criteria decision analysis (MCDA) is arising as a valuable tool to support healthcare decisi...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Diaby V,Goeree R

更新日期：2014-02-01 00:00:00

abstract：AIMS:To estimate the direct and indirect costs associated with disability due to multiple sclerosis (MS) in Poland. METHODS:Recently a cost-of-illness study was conducted in the Czech Republic, involving 909 patients with different levels of disability (the COMS study). Data on resource use from this trial was extrapo...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Szmurło D,Fundament T,Ziobro M,Kruntorádová K,Doležal T,Głogowski C

更新日期：2014-06-01 00:00:00